Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine

AIDS

Volumn 14, Issue 10, 2000, Pages 1365-1374

  Sabbaj, Steffanie ^a,g   Mulligan, Mark J ^a,b,e,g   Hsieh, Ray Hahn ^c   Belshe, Robert B ^d   McGhee, Jerry R ^b   Schwartz, D ^f   Burke, D ^f   Gorse, Geoffrey J ^d   Frey, Sharon ^d   Mestecky, Jiri ^g   Jackson, Susan ^g   Gnann, John W ^g   Goepfert, Paul A ^g   Dolin, Raphael ^h   Keefer, Michael C ^h   Evans, Thomas G ^h   McElrath, M Julianna ⁱ   Corey, Lawrence ⁱ   Graham, Barney S ^j   Wright, Peter ^j   Spearman, Paul ^j   Matthews, Thomas ^k   Montefiori, David ^k   Weinhold, Kent ^k   Bolognesi, Dani ^k   Allen, Mary ^l   Savarese, Barbara ^l   more..

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c EMMES CORPORATION   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k DUKE UNIVERSITY   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

Cellular immunity; Cytokines; T helper lymphocytes; Th1 Th2; Vaccine

Indexed keywords

ALVAC HIV; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIVE VACCINE; MESSENGER RNA; VCP 205; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MONONUCLEAR CELL; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; AIDS VACCINES; AVIPOXVIRUS; CYTOKINES; GENE EXPRESSION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; NEUTRALIZATION TESTS; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0033939889     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007070-00009     Document Type: Article

References (45)

1. 1. Clerici M ,Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994, 15:575-581.
2. 2. Klein SA, Dobmeyer JM, Dobmeyer TS et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997, 11:1111-1118.
3. 3. Mosmann TR. Cytokine patterns during the progression to AIDS. Science 1994, 265:193-194.
4. 4. Borrow P, Lewicki H, Hahn BH, Shaw GM ,Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
5. 5. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
6. 6. Legrand E, Pellegrin I, Neau D et al. Course of specific T lymphocyte cytoloxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. AIDS Res Hum Retroviruses 1997, 13:1383-1394.
7. 7. Musey L, Hughes J, Schacker T, Shea T, Corey L ,McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
8. 8. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
9. 9. Pantaleo G, Demarest JF, Schacker T et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997, 94:254-258.
10. 10. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
11. 11. Harrer T, Harrer E, Barbosa P et al. Recognition of two over-lapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. J Immunol 1998, 161:4875-4881.
12. 12. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of Gagspecific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372.
13. 13. Rinaldo C, Huang XL, Fan ZF et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995, 69:5838-5842.
14. 14. Herr W, Protzer U, Lohse AW, Gerken G, Meyer zum Buschenfelde KH ,Wolfel T. Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J Infect Dis 1998, 178: 260-265.
15. 15. Pinto LA, Sullivan J, Berzofsky JA et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995, 96:867-876.
16. 16. Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian. Nat Med 1995, 1:59-64.
17. 17. Rowland-Jones SL, Nixon DF, Aldhous MC et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993, 341:860-861.
18. 18. Borrow P, Lewicki H, Wei X et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTL) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211.
19. 19. Montefiori DC, Pantaleo G, Fink LM et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996, 173:60-67.
20. 20. Pantaleo G, Menzo S, Vaccarezza M et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
21. 21. Pilgrim AK, Pantaleo G, Cohen OJ et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997, 176:924-932.
22. 22. Schonning K, Nielsen C, Iversen J, Nielsen JO ,Hansen JE. Neutralizing antibodies in slowly progressing HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:400-407.
23. 23. Zhang YJ, Fracasse C, Fiore JR et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 1997, 176:1180-1187.
24. 24. Evans TG, Fitzgerald T, Gibbons DC, Keefer MC, Soucier H. Th1/ Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. Clin Exp Immunol 1998, 111:243-250.
25. 25. Bollinger RC, Quinn TC, Liu AY et al. Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication. AIDS Res Hum Retroviruses 1993, 9:1067-1077.
26. 26. Gorse GJ, Corey L, Patel GB et al. HIV-1 MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1 MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999, 15:115-1132.
27. 27. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA ,Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
28. 28. Abbas AK, Murphy KM ,Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
29. 29. Fresno M, Kopf M ,Rivas L. Cytokines and infectious diseases. Immunol Today 1997, 18:56-58.
30. 30. Clerici M, Hakim FT, Venzon DJ et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993, 91:759-765.
31. 31. Maizels RM, Bundy DA, Selkirk ME, Smith DF, Anderson RM. Immunological modulation and evasion by helminth parasites in human populations. Nature 1993, 365:797-805.
32. 32. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994, 12:227-257.
33. 33. Sher A, Gazzinelli RT, Oswald IP et al. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 1992, 127:183-204.
34. 34. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. [Published erratum appears in Science 1992, 255:12] Science 1991, 254:277-279.
35. 35. Belshe RB, Gorse GJ, Mulligan MJ et al. Rapid induction of HIV-1 immune responses by canarypox (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998, 12:2407-2415.
36. 36. Marinaro M, Boyaka PN, Finkelman FD et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997, 185:415-427.
37. 37. Fujihashi K, Beagley KW, Kono Y et al. Gingival mononuclear cells from chronic inflammatory periodontal tissues produce interleukin (IL)-5 and IL-6 but not IL-2 and IL-4. Am J Pathol 1993, 142:1239-1250.
38. 38. Fujihashi K, Yamamoto M, Hiroi T, Bamberg TV, McGhee JR, Kiyono H. Selected Th1 and Th2 cytokine mRNA expression by CD4(+) T cells isolated from inflamed human gingival tissues. Clin Exp Immunol 1996, 103:422-428.
39. 39. Clements-Mann ML, Weinhold K, Matthews TJ et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998. 177:1230-1246.
40. 40. McElrath MJ, Corey L, Berger D et al. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994, 169:41-47.
41. 41. Picard O, Achour A, Bernard J et al. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. J Acquir Immune Defic Syndr 1992, 5:539-546.
42. 42. Cooney EL, McElrath MJ, Corey L et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993, 90:1882-1886.
43. 43. Graham BS, Belshe RB, Clements ML et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992, 166:244-252.
44. 44. Kalams SA, Buchbinder SP, Rosenberg ES et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999, 73:6715-6720.
45. 45. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.